MINT Study Results Show Clinically Meaningful and Statistically Significant Efficacy in AChR+ and MuSK+ Patients First and Only Phase 3 Placebo-Controlled gMG Trial for a Biologic That Tapered Cortico
The Investment Committee discuss the latest Calls Of The Day.
The pharma company has a lot riding on its experimental obesity drug MariTide.
Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech's drug pipeline.
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Income stocks can be wise additions to your portfolio in any market environment.
The Investment Committee give you their top stocks to watch for the second half.

2 Biotech Stocks to Buy Hand Over Fist in October

10:15am, Wednesday, 09'th Oct 2024
These longtime leading biotech stocks still have plenty of upside ahead.
In this article, we will take a look into Amgen Inc's (AMGN, Financial) DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow as i
Investing in the most popular players in the space isn't the only valid approach.
These dividend stocks are great picks as the fall season gets underway.

Buy 2 October Dogs Of The Dow And Watch 5 More

02:38am, Saturday, 05'th Oct 2024
"The Dow® [adds a stock] if the company has an excellent reputation,
Amgen (AMGN) concluded the recent trading session at $319.66, signifying a +0.69% move from its prior day's close.
With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be the next immunology stock to soar on the Nasdaq? Investors who buy now can ge
In the most recent trading session, Amgen (AMGN) closed at $317.48, indicating a -0.7% shift from the previous trading day.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE